Issue
Med Sci (Paris)
Volume 37, Number 4, Avril 2021
Nos jeunes pousses ont du talent !
Page(s) 406 - 408
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2021043
Published online 28 April 2021
  1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018 ; 50 : 74–87. [Google Scholar]
  2. Wästerlid T, Harrysson S, Andersson TM, et al. Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. Am J Hematol 2020; 95 : 740–8. [Google Scholar]
  3. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003 ; 22 : 7359–7368. [Google Scholar]
  4. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005 ; 139 : 439–446. [Google Scholar]
  5. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010 ; 116 : 2040–2045. [Google Scholar]
  6. Zhang JY, Zhang PP, Zhou WP, et al. L-type Cav 1.2 calcium channel-α-1C regulates response to rituximab in diffuse large B-cell lymphoma. Clin Cancer Res 2019 ; 25 : 4168–4178. [Google Scholar]
  7. Babiker HM, Glode AE, Cooke LS, Mahadevan D. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs 2018 ; 27 : 407–412. [Google Scholar]
  8. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother 2019 ; 109 : 2415–2426. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.